Benjamin Edwards Inc. Sells 3,768 Shares of Stryker Corporation $SYK

Key Points

• Benjamin Edwards Inc. trimmed its position in Stryker by 2.3%, selling 3,768 shares and leaving 160,366 shares worth about $56.38 million at the end of the quarter.
• Stryker missed Q1 estimates (adjusted EPS $2.60 vs. $2.98 expected; revenue $6.02B vs. $6.34B), attributing weakness to a cyber incident, but management maintained FY2026 guidance of $14.90–$15.10 adjusted EPS and 8–9.5% organic sales growth.
• Director Ronda E. Stryker sold 250,000 shares in February for roughly $90.73 million (a 9.23% decline in her stake), and several analysts have cut price targets though the consensus rating remains a "Moderate Buy" with an average target near $401.

Benjamin Edwards Inc. lessened its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 160,366 shares of the medical technology company's stock after selling 3,768 shares during the quarter. Benjamin Edwards Inc.'s holdings in Stryker were worth $56,382,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of SYK. LVZ Inc. lifted its position in Stryker by 3.3% in the 4th quarter. LVZ Inc. now owns 4,881 shares of the medical technology company's stock worth $1,716,000 after buying an additional 155 shares during the last quarter. Forza Wealth Management LLC lifted its position in Stryker by 4.4% in the 4th quarter. Forza Wealth Management LLC now owns 924 shares of the medical technology company's stock worth $325,000 after buying an additional 39 shares during the last quarter. SevenBridge Financial Group LLC lifted its position in Stryker by 4.1% in the 4th quarter. SevenBridge Financial Group LLC now owns 1,264 shares of the medical technology company's stock worth $451,000 after buying an additional 50 shares during the last quarter. Cornerstone Planning Group LLC lifted its position in Stryker by 2,057.1% in the 4th quarter. Cornerstone Planning Group LLC now owns 151 shares of the medical technology company's stock worth $54,000 after buying an additional 144 shares during the last quarter. Finally, PFA Pension Forsikringsaktieselskab bought a new stake in Stryker in the 4th quarter worth approximately $94,018,000. Institutional investors own 77.09% of the company's stock.

Stryker Price Performance

Shares of Stryker stock opened at $295.43 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. Stryker Corporation has a one year low of $294.55 and a one year high of $404.87. The stock has a market capitalization of $113.15 billion, a P/E ratio of 35.17, a price-to-earnings-growth ratio of 1.84 and a beta of 0.92. The business's 50 day simple moving average is $345.67 and its two-hundred day simple moving average is $356.95.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.74%. The business had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $6.34 billion. During the same period last year, the firm posted $2.84 earnings per share. Stryker's quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts forecast that Stryker Corporation will post 14.91 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker's payout ratio is 41.90%.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the business's stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares of the company's stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on SYK shares. Canaccord Genuity Group dropped their target price on Stryker from $435.00 to $400.00 and set a "buy" rating for the company in a research report on Friday. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research note on Saturday. UBS Group decreased their price target on Stryker from $400.00 to $380.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 17th. JPMorgan Chase & Co. decreased their price target on Stryker from $445.00 to $400.00 and set an "overweight" rating on the stock in a research note on Friday. Finally, TD Cowen cut Stryker from a "buy" rating to a "hold" rating and set a $387.00 price target on the stock. in a research note on Monday, January 26th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $401.43.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.